Essential Thrombocythemia Pipeline Summary

DelveInsight’s, “Essential Thrombocythemia - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Essential Thrombocythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Essential Thrombocythemia: Understanding

Essential Thrombocythemia: Overview

Essential Thrombocythemia (ET) is a rare blood disease in which the bone marrow produces too many platelets. High numbers of platelets may lead to a thrombus, a blood clot that forms in a blood vessel. This can cause serious health problems such as a stroke, heart attack or pulmonary embolism. It is one of a related group of blood cancers known as “myeloproliferative neoplasms” (MPNs) in which cells in the bone marrow that produce the blood cells develop and function abnormally. ET usually develops very slowly. It can affect people of any age. But it usually affects middle aged and older people. The average age at diagnosis is 50 to 70 years, although it can affect children and young adults.

Essential Thrombocythemia (ET) often develops slowly and may be detected during routine blood tests before symptoms appear. As the disease progresses, symptoms are mainly related to blood clots or, less commonly, bleeding, and may include headaches, dizziness, blurred vision, fatigue, burning or tingling in the hands and feet, and abdominal discomfort due to an enlarged spleen.

Essential Thrombocythemia (ET) is a chronic Philadelphia chromosome-negative myeloproliferative neoplasm characterized by the clonal proliferation of hematopoietic stem cells, resulting in excessive production of platelets. The disease is primarily driven by acquired somatic mutations in the JAK2, CALR, or MPL genes, which lead to constitutive activation of the JAK-STAT signaling pathway, promoting abnormal megakaryocyte proliferation, survival, and platelet production. Approximately 50–60% of patients harbor the JAK2 V617F mutation, 20–30% have CALR mutations, and 3–5% carry MPL mutations, while a small proportion are triple-negative, lacking all three driver mutations. Although the exact cause of these genetic alterations remains unknown, they are acquired rather than inherited and occur during a person's lifetime. Additional genetic and epigenetic abnormalities may also contribute to disease progression and clinical heterogeneity, increasing the risk of thrombotic events, hemorrhage, and, in some cases, transformation to myelofibrosis or acute myeloid leukemia.

Essential thrombocythemia may be considered in symptom-free patients when a blood test (done as part of a periodic health examination) shows a higher than normal platelet count. Other tests include a bone marrow biopsy, molecular testing for JAK2, CALR, and MPL mutations, a chest X-ray, and an abdominal ultrasound to assess the size of the spleen. These investigations help confirm the diagnosis, distinguish ET from other myeloproliferative neoplasms, and exclude secondary causes of thrombocytosis.

Patients with low risk for clotting are usually observed without any therapy; low-dose aspirin can be considered. Patients with high risk for clotting require medical therapy to decrease platelets to normal levels, and are given low-dose aspirin to prevent clotting. The drugs most commonly used to treat ET are hydroxyurea (Hydrea®), anagrelide (Agrylin®) and interferon alfa (immediate-release preparations Intron® A and Roferon-A® and sustained-release preparations PEG-Intron® and Pegasys®). Moreover, Radioactive phosphorus (P-32) a type of internal radiotherapy could be used as well.

"Essential Thrombocythemia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Essential Thrombocythemia pipeline landscape is provided which includes the disease overview and Essential Thrombocythemia treatment guidelines. The assessment part of the report embraces, in depth Essential Thrombocythemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Essential Thrombocythemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Essential Thrombocythemia R&D. The therapies under development are focused on novel approaches to treat/improve Essential Thrombocythemia.

Essential Thrombocythemia Emerging Drugs Chapters

This segment of the Essential Thrombocythemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Essential Thrombocythemia Emerging Drugs

• INCA033989: Incyte

INCA033989 is a novel, first-in-class monoclonal antibody designed to selectively target the mutant calreticulin (mutCALR) protein expressed on malignant hematopoietic cells while sparing normal cells. INCA033989 binds specifically to the mutant CALR neoepitope, promoting immune-mediated elimination of mutant cells through antibody-dependent cellular cytotoxicity (ADCC) and inhibiting the growth of the malignant clone. This targeted mechanism aims to address the underlying driver of CALR-mutated ET while minimizing effects on healthy hematopoietic cells. Currently, the drug is in the Phase III stage of development for the treatment of Essential Thrombocythemia.

• Dencatistat (STP938): Step Pharma

Dencatistat (STP938) is a first-in-class, orally bioavailable, highly selective inhibitor of cytidine triphosphate synthase 1 (CTPS1) being investigated for the treatment of essential thrombocythemia (ET). By selectively inhibiting CTPS1, a key enzyme in the de novo pyrimidine synthesis pathway, dencatistat reduces the production of cytidine triphosphate (CTP), thereby limiting DNA synthesis and the proliferation of rapidly dividing hematopoietic cells responsible for excessive platelet production. Through this novel mechanism of action, STP938 aims to normalize platelet counts while offering a targeted therapeutic approach for patients with ET who are resistant or intolerant to hydroxyurea. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Essential Thrombocythemia.

Further product details are provided in the report……..

Essential Thrombocythemia: Therapeutic Assessment

This segment of the report provides insights about the different Essential Thrombocythemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Essential Thrombocythemia

There are approx. 10+ key companies which are developing the therapies Essential Thrombocythemia. The companies which have their Essential Thrombocythemia drug candidates in the most advanced stage, i.e. Phase III include, Incyte and others.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Essential Thrombocythemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Essential Thrombocythemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Essential Thrombocythemia drugs.

Essential Thrombocythemia Report Insights

• Essential Thrombocythemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Essential Thrombocythemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Essential Thrombocythemia drugs?
• How many Essential Thrombocythemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Essential Thrombocythemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Essential Thrombocythemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Essential Thrombocythemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte
• Step Pharma
• Jubilant Therapeutics
• Merck Sharp & Dohme LLC

Key Products

• INCA033989
• Dencatistat (STP938)
• JBI-802
• Bomedemstat(MK-3543)